Rubis SCA (0RTS)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 35.78 |
|---|---|
| 52-week range | 29.98 – 37.08 |
| Return, 1 month / 3 months | +2.3% / +9.5% |
| Return, 1 year / 3 years | +19.2% / +125.6% |
| Trend | Uptrend |
| RSI (14) | 58 |
| Volatility (1 year) | 21.9% |
| Worst drawdown (1 year) | -11.4% |
| Average daily value traded | 1.14M EUR |
| Dividend yield | 5.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Rubis SCA is a French company that distributes petroleum products and provides bulk liquid storage. Through its distribution arm it supplies fuels, liquefied petroleum gas and related products to retail, commercial and industrial customers in Europe, the Caribbean and Africa. Its terminal business stores and handles liquid bulk products such as fuels and chemicals at port facilities. The company is based in France and serves customers across several regions through local subsidiaries and branded service stations.
The shares are listed on the London Exchange in UK under the code 0RTS, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Rubis SCA (0RTS) trades on the London Exchange in UK. It last closed at EUR 35.78 on 23 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 355 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 19.2% and over the last three months it rose 9.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 75 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 7.9% | ||
| From 52-week high | -2.9% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 9.5% | ||
| 6-month return | 10.6% | ||
| 12-month return, skipping the last month | 16.6% | ||
| Stability (higher is calmer) | 88 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -11.4% | ||
| Liquidity | 54 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.14M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 61 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.8% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.2% |
|---|---|
| 1 month | +2.3% |
| 3 months | +9.5% |
| 6 months | +10.6% |
| 1 year | +19.2% |
| 3 years | +125.6% |
| 5 years | +84.6% |
Signals
| 50-day / 200-day average | 34.75 / 33.15 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.70 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 16 Jun 2026 | EUR 2.0700 |
| 17 Jun 2025 | EUR 2.0300 |
| 6 Nov 2024 | EUR 0.7500 |
| 14 Jun 2024 | EUR 1.9800 |
| 13 Jun 2023 | EUR 1.9200 |
| 14 Jun 2022 | EUR 1.8600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.